Molecular testing on endobronchial ultrasound (EBUS) fine needle aspirates (FNA): Impact of triage

2017 ◽  
Vol 46 (2) ◽  
pp. 122-130 ◽  
Author(s):  
Simon Sung ◽  
John P. Crapanzano ◽  
David DiBardino ◽  
David Swinarski ◽  
William A. Bulman ◽  
...  
Keyword(s):  
Endobronchial Ultrasound ◽  
Molecular Testing ◽  
Fine Needle ◽  
Fine Needle Aspirates

scholarly journals Adequacy of Core Needle Biopsy Specimens and Fine-Needle Aspirates for Molecular Testing of Lung Adenocarcinomas

2015 ◽  
Vol 143 (2) ◽  
pp. 193-200 ◽  
Author(s):  
Frank Schneider ◽  
Matthew A. Smith ◽  
Molly C. Lane ◽  
Liron Pantanowitz ◽  
Sanja Dacic ◽  
...  
Keyword(s):  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Molecular Testing ◽  
Core Needle ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
Biopsy Specimens ◽  
Lung Adenocarcinomas

scholarly journals Molecular testing for BRAFV600E and RAS mutations from cytoscrapes of thyroid fine needle aspirates: A single-center pilot study

2020 ◽  
Vol 37 (4) ◽  
pp. 174
Author(s):  
Radhika Srinivasan ◽  
Ojas Gupta ◽  
Upasana Gautam ◽  
Muralidaran Chandrasekhar ◽  
Arvind Rajwanshi ◽  
...  
Keyword(s):  
Pilot Study ◽  
Molecular Testing ◽  
Single Center ◽  
Fine Needle ◽  
Ras Mutations ◽  
Fine Needle Aspirates

Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel

2021 ◽  
pp. jclinpath-2021-207429
Author(s):  
Roberta Sgariglia ◽  
Mariantonia Nacchio ◽  
Ilaria Migliatico ◽  
Elena Vigliar ◽  
Umberto Malapelle ◽  
...  
Keyword(s):  
Local Level ◽  
Needle Aspiration ◽  
Molecular Testing ◽  
Health Coverage ◽  
Fine Needle ◽  
Fine Needle Aspirates ◽  
Gene Test ◽  
Thyroid Fine Needle Aspiration ◽  
Thyroid Fna ◽  
Prohibitive Cost

AimsIn thyroid cytopathology, the undetermined diagnostic categories still pose diagnostic challenges. Although next-generation sequencing (NGS) is a promising technique for the molecular testing of thyroid fine-needle aspiration (FNA) specimens, access to such technology can be difficult because of its prohibitive cost and lack of reimbursement in countries with universal health coverage. To overcome these issues, we developed and validated a novel custom NGS panel, Nexthyro, specifically designed to target 264 clinically relevant mutations involved in thyroid tumourigenesis. Moreover, in this study, we compared its analytical performance with that of our previous molecular testing strategy.MethodsThe panel, which includes 15 genes (BRAF, EIF1AX, GNAS, HRAS, IDH1, KRAS, NF2, NRAS, PIK3CA, PPM1D, PTEN, RET, DICER1, CHEK2, TERT promoter), was validated with a cell-line derived reference standard and 72 FNA archival samples previously tested with the 7-gene test.ResultsNexthyro yielded 100% specificity and detected mutant alleles at levels as low as 2%. Moreover, in 5/72 (7%) FNAs, it detected more clinically relevant mutations in BRAF and RAS genes compared with the 7-gene test. Nexthyro also revealed better postsequencing metrics than the previously adopted commercial ‘generic’ NGS panel.ConclusionOur comparative analysis indicates that Nexthyro is a reliable NGS panel. The study also implies that a custom-based solution for routine thyroid FNA is sustainable at the local level, allowing patients with undetermined thyroid nodules affordable access to NGS.

scholarly journals Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms

2018 ◽  
Vol 46 (4) ◽  
pp. 320-325 ◽  
Author(s):  
Kristen L. Partyka ◽  
Melissa L. Randolph ◽  
Karen A. Lawrence ◽  
Harvey Cramer ◽  
Howard H. Wu
Keyword(s):  
Molecular Testing ◽  
Fine Needle ◽  
Fine Needle Aspirates
Sign in / Sign up

Export Citation Format

Share Document